Medicare Enrolled
Dr. Emily Whitman-Purves, M.D.
Medical Oncology · Columbus, OH
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Whitman-Purves from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Whitman-Purves?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Whitman-Purves
Dr. Emily Whitman-Purves is a medical oncology specialist in Columbus, OH, with 16 years of NPI registration. Based on federal Medicare data, Dr. Whitman-Purves performed 60,690 Medicare services across 1,272 unique beneficiaries.
Between the years covered by Open Payments, Dr. Whitman-Purves received a total of $3,551 from 40 pharmaceutical and/or device companies across 130 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Whitman-Purves is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 7% volume in OH
$3,551 industry payments
Medicare Practice Summary
Medicare Utilization ↗60,690
Medicare services
Top 7% in OH for medical oncology
1,272
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,793 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Paclitaxel chemotherapy injection | 18,268 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 15,100 | $43 | $157 |
| Anti-nausea injection (aprepitant) | 12,090 | $1 | $6 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
7,209 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,010 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,260 | $1 | $41 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
661 | $8 | $29 |
| Anti-nausea injection (ondansetron/Zofran) | 656 | $0 | $3 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
516 | $2 | $39 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
405 | $89 | $390 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
319 | $93 | $421 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
272 | $21 | $103 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
245 | $0 | $11 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
167 | $6 | $126 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
151 | $1 | $4 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
143 | $11 | $66 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
127 | $8 | $9 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
108 | $21 | $164 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
106 | $10 | $67 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
98 | $47 | $205 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
84 | $70 | $210 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
78 | $130 | $550 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
77 | $41 | $377 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
76 | $156 | $747 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
73 | $5 | $16 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
71 | $54 | $277 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
61 | $3 | $11 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
41 | $2 | $9 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
39 | $46 | $208 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
39 | $43 | $180 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
36 | $25 | $121 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
31 | $61 | $214 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
23 | $9 | $40 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
21 | $121 | $509 |
| New patient office visit, complex (60-74 min) | 17 | $158 | $673 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
12 | $94 | $406 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.3% high complexity
95.5% medium
3.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,551
Total received (2018-2024)
Avg $507/year across 7 years
Top 46% in OH for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
130
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,178 (61.3%)
Other
Charitable contributions, space rental, and other categories
$980 (27.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$392 (11.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,310
2023
$429
2022
$499
2021
$593
2020
$549
2019
$57
2018
$115
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$980
Eisai Inc.
$103
EMD Serono, Inc.
$54
Gilead Sciences, Inc.
$47
GlaxoSmithKline, LLC.
$27
AstraZeneca Pharmaceuticals LP
$26
Aveo Pharmaceuticals, Inc.
$21
Genentech USA, Inc.
$20
Iovance Biotherapeutics, Inc.
$17
Kite Pharma, Inc.
$15
Top 3 companies account for 86.8% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,017
Eisai Inc.
$376
Athenex Pharmaceutical Division, LLC
$350
Gilead Sciences, Inc.
$159
Regeneron Pharmaceuticals, Inc.
$129
EMD Serono, Inc.
$107
Clovis Oncology, Inc.
$96
Amgen Inc.
$89
Daiichi Sankyo Inc.
$87
Genentech USA, Inc.
$86
GlaxoSmithKline, LLC.
$76
AstraZeneca Pharmaceuticals LP
$68
Taiho Oncology, Inc.
$68
E.R. Squibb & Sons, L.L.C.
$66
BeiGene USA, Inc.
$65
PFIZER INC.
$63
Celgene Corporation
$56
Janssen Biotech, Inc.
$50
Takeda Pharmaceuticals U.S.A., Inc.
$48
Coherus Biosciences Inc.
$46
Seagen Inc.
$40
Exelixis Inc.
$39
Regeneron Healthcare Solutions, Inc.
$37
JAZZ PHARMACEUTICALS INC.
$30
Foundation Medicine, Inc.
$27
EISAI INC.
$26
GENZYME CORPORATION
$26
Alexion Pharmaceuticals, Inc.
$23
Aveo Pharmaceuticals, Inc.
$21
Merck Sharp & Dohme LLC
$21
AbbVie, Inc.
$21
CTI BioPharma Corp.
$19
Iovance Biotherapeutics, Inc.
$17
Acceleron Pharma, Inc.
$16
AMAG Pharmaceuticals, Inc.
$16
Kite Pharma, Inc.
$15
Pharmacyclics LLC, an AbbVie Company
$14
Genmab U.S., Inc.
$13
ADC Therapeutics America, Inc.
$13
Dova Pharmaceuticals
$13
Top 3 companies account for 49.1% of all-time payments
Associated products mentioned in payments ›
Alecensa · Amtagvi · BRUKINSA · Bavencio · Cabometyx · DARZALEX · Doptelet · ENHERTU · ERLEADA · Enhertu · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INQOVI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LYNPARZA · Lenvima · Lonsurf · NINLARO · Nplate · OJJAARA · OPDIVO · PADCEV · PLUVICTO · Phesgo · REBLOZYL · Reblozyl · Revlimid · Rubraca · SCEMBLIX · TUKYSA · Tivdak · Trodelvy · ULTOMIRIS · Udenyca · Venclexta · Vonjo · XGEVA · Yescarta · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (61%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
70
Per 100K population
5.3
County median income
$73,795
Nearest hospital
RIVER VISTA HEALTH AND WELLNESS LLC
3.7 mi
3.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Whitman-Purves is a mixed practice specialist, with above-average Medicare volume (top 7% in OH), with low-engagement industry engagement, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Whitman-Purves experienced with paclitaxel chemotherapy injection?
Based on Medicare claims data, Dr. Whitman-Purves performed 18,268 paclitaxel chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Whitman-Purves receive payments from pharmaceutical companies?
Yes. Dr. Whitman-Purves received a total of $3,551 from 40 companies across 130 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Whitman-Purves's costs compare to other medical oncologists in Columbus?
Dr. Whitman-Purves's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Whitman-Purves) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Columbus
Browse medical oncologists in Columbus ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in OH
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in OH
Which OH medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Eisai Inc. Payments to Doctors
See all physicians who received payments from Eisai Inc.
By company
Athenex Pharmaceutical Division, LLC Payments to Doctors
See all physicians who received payments from Athenex Pharmaceutical Division, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology